Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(17)30920-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study.
Leuk Lymphoma
December 2024
iOMEDICO, Freiburg im Breisgau, Germany.
Therapy adherence can significantly influence the outcome of cancer patients. The prospective, non-interventional CARO study (NCT02970747) investigated adherence, effectiveness, and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) in the German real-world setting. In total, 359 patients were included at 69 sites.
View Article and Find Full Text PDFEstablishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1.
Hum Cell
December 2024
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Chondrosarcoma (CS) is a malignant tumor that produces cartilaginous matrix and is the second most common primary bone sarcoma. CS encompasses a range of histological subtypes, with high-grade conventional central CS being particularly rare, occurring at a rate of 1.81 cases per 1 million person-years.
View Article and Find Full Text PDFSurvival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison.
Future Oncol
November 2024
Bristol Myers Squibb, Princeton, NJ, USA.
Aims: Limited head-to-head data exist for daratumumab plus pomalidomide and dexamethasone (DPd) and non-pomalidomide-containing triplet regimens to treat relapsed/refractory multiple myeloma (RRMM). This study conducted population-adjusted indirect comparisons of overall survival (OS) for DPd vs. daratumumab, carfilzomib, and dexamethasone (DKd) and daratumumab, bortezomib, and dexamethasone (DVd).
View Article and Find Full Text PDFAllocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.
Blood Cancer J
November 2024
Hematology Department, CHU Nantes, Nantes, France.
The International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The phase 3 ICARIA-MM (isatuximab-pomalidomide-dexamethasone vs. pomalidomide-dexamethasone) and IKEMA (isatuximab-carfilzomib-dexamethasone vs.
View Article and Find Full Text PDFEconomic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Risk Manag Healthc Policy
November 2024
Department of Nuclear Medicine/PET Image Center, The Second Xiangya Hospital of Central South University, Changsha, People's Republic of China.
Objective: To assess the cost-effectiveness of adding daratumumab to carfilzomib and dexamethasone (KdD) in patients with relapsed or refractory multiple myeloma (RRMM).
Materials And Methods: A Markov model was established to estimate health and economic outcomes of carfilzomib and dexamethasone (Kd) with or without daratumumab for RRMM patients over a lifetime horizon. The patients and intervention of the two arms were modeled according to the CANDOR trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!